GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telix Pharmaceuticals Ltd (OTCPK:TLPPF) » Definitions » Earnings per Share (Diluted)

Telix Pharmaceuticals (Telix Pharmaceuticals) Earnings per Share (Diluted) : $0.01 (TTM As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Telix Pharmaceuticals Earnings per Share (Diluted)?

Telix Pharmaceuticals's Earnings per Share (Diluted) for the six months ended in Dec. 2023 was $0.04. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.01.

Telix Pharmaceuticals's EPS (Basic) for the six months ended in Dec. 2023 was $0.04. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.01.

Telix Pharmaceuticals's EPS without NRI for the six months ended in Dec. 2023 was $0.04. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $0.01.

During the past 9 years, Telix Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was -41.20% per year. The lowest was -109.20% per year. And the median was -61.20% per year.


Telix Pharmaceuticals Earnings per Share (Diluted) Historical Data

The historical data trend for Telix Pharmaceuticals's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telix Pharmaceuticals Earnings per Share (Diluted) Chart

Telix Pharmaceuticals Annual Data
Trend Sep99 Sep00 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only -0.08 -0.13 -0.20 -0.23 0.01

Telix Pharmaceuticals Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.12 -0.16 -0.07 -0.03 0.04

Competitive Comparison of Telix Pharmaceuticals's Earnings per Share (Diluted)

For the Biotechnology subindustry, Telix Pharmaceuticals's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Telix Pharmaceuticals's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Telix Pharmaceuticals's PE Ratio distribution charts can be found below:

* The bar in red indicates where Telix Pharmaceuticals's PE Ratio falls into.



Telix Pharmaceuticals Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Telix Pharmaceuticals's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(3.488-0)/319.181
=0.01

Telix Pharmaceuticals's Earnings Per Share (Diluted) for the quarter that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (Q: Dec. 2023 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(13.073-0)/320.740
=0.04

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Telix Pharmaceuticals  (OTCPK:TLPPF) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Telix Pharmaceuticals Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Telix Pharmaceuticals's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Telix Pharmaceuticals (Telix Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
55 Flemington Road, Suite 401, North Melbourne, Melbourne, VIC, AUS, 3051
Telix Pharmaceuticals Ltd is a clinical-stage biotechnology company engaged in developing and commercializing molecularly-targeted radiation therapy to address the unmet needs in the management of prostate, renal (kidney) and glioblastoma (brain) cancer. Geographically, it operates in Australia, the United States, Belgium, and Japan.